Teva Pharmaceutical Industries Limited : American Depositary Shares Securities Litigation
On or around 12/14/2018 (Ongoing date of last review)
Filing Date: November 06, 2016
According to the law firm press release, the lawsuit alleges throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.
On April 3, 2017, the Court issued an Order consolidating cases and transferring the consolidated action to the District of Connecticut.
On July 11, 2017, the Court appointed Lead Plaintiff and Counsel. Lead Plaintiff filed a Complaint on August 2.
An amended Complaint was filed on September 5, 2017. This was followed by the filing of the consolidated Complaint on September 11. Defendants filed Motions to Dismiss the consolidated Complaint on December 1. On April 3, 2018, the Court issued an Order granting Defendants' Motions to Dismiss the consolidated Complaint. Lead Plaintiff was given leave to file an amended consolidated Complaint. Lead Plaintiff filed an amended consolidated Complaint on June 22.
Company & Securities Information
Defendant: Teva Pharmaceutical Industries Limited
Industry: Major Drugs
Ticker Symbol: TEVA
Company Market: New York SE
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Amram Galmi, et al. v. Teva Pharmaceutical Industries Limited , et al.